Michael L. Grossbard, MD

Articles

Fellows on Film: What Makes a Good Mentor for an Oncology Fellow?

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.

Fellows on Film: How Do Fellowship Directors Select Applicants?

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the process of selecting applicants to be accepted into an oncology fellowship.

Fellows on Film: Is the General Oncologist Still a Possibility?

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss whether it's still a possibility to be a general oncologist following an oncology fellowship.

Fellows on Film: The Compact Style of Oncology Fellowship Training

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the compact style that comprises oncology fellowship training.

Fellows on Film: Selecting a Mentor During Oncology Fellowship

January 31st 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share advice in selecting a mentor during an oncology fellowship.

Fellows on Film: Lessons Learned During Oncology Fellowship

January 28th 2022

Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, share their experiences as a fellowship director and an oncology fellow, respectively.

Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

May 21st 2020

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

May 20th 2020

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Dr. Grossbard on the Activity of Venetoclax in Follicular Lymphoma

April 24th 2020

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

Dr. Grossbard on the DYNAMO Study With Duvelisib in Follicular Lymphoma

April 17th 2020

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

Dr. Grossbard on the Role of MRD in Follicular Lymphoma

March 24th 2020

Michael L. Grossbard, MD, discusses the role of minimal residual disease in follicular lymphoma.

Dr. Grossbard on the GALLIUM Study in Follicular Lymphoma

March 17th 2020

Michael L. Grossbard, MD, professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, and section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, discusses the results of the phase III GALLIUM study in follicular lymphoma.

Dr. Grossbard on the Utility of PI3K Inhibitors in Follicular Lymphoma

March 5th 2020

Michael L. Grossbard, MD, discusses the utility of PI3K inhibitors in follicular lymphoma.